A pharmacogenetic study of docetaxel and thalidomide in patients with castration-resistant prostate cancer using the DMET genotyping platform

J. F. Deeken, T. Cormier, D. K. Price, T. M. Sissung, S. M. Steinberg, K. Tran, D. J. Liewehr, W. L. Dahut, X. Miao, W. D. Figg

Research output: Contribution to journalArticlepeer-review

68 Scopus citations

Abstract

The anticancer agent docetaxel shows significant inter-individual variation in its pharmacokinetic and toxicity profile. Thalidomide is an active anticancer agent and also shows wide pharmacological variation. Past pharmacogenetic research has not explained this variation. Patients with prostate cancer enrolled in a randomized phase II trial using docetaxel and thalidomide versus docetaxel alone were genotyped using the Affymetrix DMET 1.0 platform, which tests for 1256 genetic variations in 170 drug disposition genes. Genetic polymorphisms were analyzed for associations with clinical response and toxicity. In all, 10 single-nucleotide polymorphisms (SNPs) in three genes were potentially associated with response to therapy: peroxisome proliferator-activated receptor-δ (PPAR-δ), sulfotransferase family, cytosolic, 1C, member 2 (SULT1C2) and carbohydrate (chondroitin 6) sulfotransferase 3 (CHST3). In addition, 11 SNPs in eight genes were associated with toxicities to treatment: spastic paraplegia 7 (pure and complicated autosomal recessive) (SPG7), CHST3, cytochrome P450, family 2, subfamily D, polypeptide 6 (CYP2D6), N-acetyltransferase 2 (arylamine N-acetyltransferase) (NAT2), ATPbinding cassette, sub-family C (CFTR/MRP), member 6 (ABCC6), ATPase, Cu\+ \+ transporting, alpha polypeptide (ATP7A), cytochrome P450, family 4, subfamily B, polypeptide 1 (CYP4B1) and solute carrier family 10 (sodium/bile acid cotransporter family), member 2 (SLC10A2). Genotyping results between drug metabolizing enzymes and transporters (DMET) and direct sequencing showed >96% of concordance. These findings highlight the role that non-CYP450 metabolizing enzymes and transporters may have in the pharmacology of docetaxel and thalidomide.

Original languageEnglish
Pages (from-to)191-199
Number of pages9
JournalPharmacogenomics Journal
Volume10
Issue number3
DOIs
StatePublished - Jun 2010
Externally publishedYes

Keywords

  • Docetaxel
  • Pharmacogenomics
  • Prostate cancer
  • Thalidomide

Fingerprint

Dive into the research topics of 'A pharmacogenetic study of docetaxel and thalidomide in patients with castration-resistant prostate cancer using the DMET genotyping platform'. Together they form a unique fingerprint.

Cite this